IMUXHIGH SIGNALFINANCIAL10-K

Immunic's financial position deteriorated significantly with stockholders' equity turning negative at -$6.7M and cash reserves declining 57% to $15.5M, creating potential going concern risks for this clinical-stage biotech.

The company's equity turning deeply negative while burning through over half its cash represents a material deterioration in financial stability that could jeopardize its ability to complete ongoing Phase 3 trials. While the company achieved important clinical milestones by completing enrollment in both ENSURE trials with over 2,200 patients, the financial strain may force difficult capital-raising decisions or strategic alternatives before trial readouts in 2026.

Comparing 2026-02-26 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

Immunic's balance sheet shows severe deterioration with stockholders' equity plunging from $18.4M to negative $6.7M, while cash and equivalents fell dramatically from $35.7M to $15.5M. Total assets declined 41% to $24.1M as current liabilities increased 38% to $30.6M, creating a concerning liquidity profile. The financial picture signals potential distress for this clinical-stage company that needs substantial capital to complete its Phase 3 program, with the cash burn rate suggesting limited runway without additional financing.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-136.2%
$18.4M→-$6.7M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
-56.6%
$35.7M→$15.5M

Cash declined 56.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-41.9%
$39.3M→$22.9M

Current assets declined 41.9% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-41.1%
$40.9M→$24.1M

Total assets contracted 41.1% — asset sales, write-downs, or balance sheet optimization underway.

Capital Expenditure
Cash Flow
-39%
$264K→$161K

Capex reduced 39% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Liabilities
Balance Sheet
+38.1%
$22.2M→$30.6M

Current liabilities surged 38.1% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+36.9%
$22.4M→$30.7M

Liabilities grew 36.9% — significant increase in debt or obligations, assess impact on financial flexibility.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-31
ADDED
On February 24, 2026, 130,464,825 shares of common stock, $0.0001 par value, were outstanding.
( Immunic," we, us, our or the "Company") is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases.
The Phase 3 ENSURE program of vidofludimus calcium in RMS, comprising twin studies evaluating efficacy, safety, and tolerability of vidofludimus calcium versus placebo, is currently ongoing.
In June 2025, we announced completion of enrollment for both ENSURE trials.
Each of the trials enrolled adult patients with active RMS at more than 100 sites in 15 countries.
+7 more — sign up free →
REMOVED
On March 15, 2025, 90,150,869 shares of common stock, $0.0001 par value, were outstanding.
("Immunic," we, us, our or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.
The Phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis ( RMS ), comprising twin studies evaluating efficacy, safety, and tolerability of vidofludimus calcium versus placebo, and the Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis ( PMS ), designed to corroborate vidofludimus calcium s neuroprotective potential, are ongoing.
Top-line data from the CALLIPER trial, for which the recruitment of 467 total patients was completed in August 2023, is expected to be available in April 2025.
Completion of the first of the ENSURE trials is currently anticipated in the second quarter of 2026; and the completion of the second ENSURE trial in the second half of 2026.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →